National Bank of Canada
CORT icon

National Bank of Canada’s Corcept Therapeutics CORT Stock Holding History

National Bank of Canada’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$46.7K Buy
1,160
+155
+15% +$5.8K ﹤0.01% 2000
2025
Q4 		$34.9K Buy
1,005
+975
+3,250% +$76.6K ﹤0.01% 2034
2025
Q3 		$2.47K Buy
+30
New +$2.17K ﹤0.01% 2564
2025
Q1 		– Sell
-834
Closed -$42K – 2899
2024
Q4 		$42K Buy
+834
New +$43.7K ﹤0.01% 1997

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

National Bank of Canada's CORT Position: Q1 2026 in Review

National Bank of Canada increased its Corcept Therapeutics (CORT) stake by 15% in Q1 2026, buying an estimated $5.8K and bringing the position to 1,160 shares worth $46.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2000.

National Bank of Canada first reported a position in CORT in Q4 2024 and has held it in 4 quarters since. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • National Bank of Canada held 1,160 shares of Corcept Therapeutics worth $46.7K as of Q1 2026.
  • National Bank of Canada bought 155 Corcept Therapeutics shares in Q1 2026, an estimated $5.8K.
  • Corcept Therapeutics made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #2000 holding.
  • National Bank of Canada first reported a position in Corcept Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • 351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.